Abstract:Scleral cross-linking(SXL), a technique that enhances the mechanical strength of scleral collagen fibers to slow myopia progression, has shown considerable potential in the field of myopia prevention and control. To date, animal studies have demonstrated that SXL can effectively improve the scleral biomechanical properties in guinea pig, rabbit, and porcine models, while significantly inhibiting abnormal axial elongation. Its therapeutic effects are mainly attributed to the regulation of genes involved in collagen synthesis and degradation, thereby improving scleral remodeling. Current approaches include riboflavin/ultraviolet A photochemical cross-linking and chemical cross-linking using agents such asgenipin, each with distinct advantages. Novel delivery systems, including wireless patches integrating microneedle drug delivery, μ-LED illumination, and ultrasonic regulation, have further enabled more precise and minimally invasive treatment. In addition, variations in treatment efficacy associated with regional characteristics in sclera properties highlight the need for individualized therapeutic strategies. Although several challenges remain, including long-term safety, applicability in pediatric populations, and standardization of protocols, SXL offers a novel approach for myopia control, particularly in pathological myopia. Future advances in drug-delivery technologies, innovative devices, and non-invasive monitoring methods are expected to facilitate its clinical translation and provide an effective strategy for controlling myopia progression and reducing associated complications.